Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 3Thoracic 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Neoplasms 3Breast Neoplasms 2Urinary Bladder Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Multiple Pulmonary Nodules 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 48Carboplatin 34Pemetrexed 28Cisplatin 25Docetaxel 23Nivolumab 21Paclitaxel 20Gemcitabine 15Magnetic Resonance Spectroscopy 14Specimen Handling 12Radiotherapy 12Cyclophosphamide 12Radiosurgery 11130-nm albumin-bound paclitaxel 11Erlotinib Hydrochloride 10Bevacizumab 10osimertinib 9Cetuximab 8Temozolomide 7Taxes 7Ipilimumab 7Biopsy 7fludarabine 6Ramucirumab 6Radiation 6veliparib 5tislelizumab 5durvalumab 5cemiplimab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Positron Emission Tomography Computed Tomography × Thoracic × Clear all
NCT05835570 2025-04-30

Integrin αvβ6-targeted PET in Malignant Tumors

Zhongnan Hospital

Recruiting
200 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡